Diplomat Announces 2nd Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Leerink Partners Raises price Target on Diplomat Pharmacy (DPLO) to $38 Following Mixed 2Q
August 10, 2016 7:07 AM EDTLeerink Partners reiterated an Outperform rating on Diplomat Pharmacy (NYSE: DPLO), and raised the price target to $38.00 (from $36.00), following the company's 2Q earnings report. DPLO reported total revenue of $1,089M, 3% below consensus of $1,118M. Adjusted EPS $0.23 was above the consensus estimates of $0.21.
Analyst... More
Diplomat Pharmacy (DPLO) Tops Q2 EPS by 2c
August 9, 2016 4:40 PM EDTDiplomat Pharmacy (NYSE: DPLO) reported Q2 EPS of $0.23, $0.02 better than the analyst estimate of $0.21. Revenue for the quarter came in at $1.09 billion versus the consensus estimate of $1.12 billion.
GUIDANCE:
Diplomat Pharmacy sees FY2016 EPS of $0.90-$0.95, versus prior guidance of... More
